MOCLOBEMIDE AND SPECIFIC SEROTONIN REUPTAKE INHIBITOR COMBINATION TREATMENT OF RESISTANT ANXIETY AND DEPRESSIVE-DISORDERS

被引：19

作者：

BAKISH, D

HOOPER, CL

WEST, DL

MILLER, C

BLANCHARD, A

BASHIR, F

机构：

[1] ROYAL OTTAWA HOSP,PSYCHOPHARMACOL UNIT,OTTAWA,ON K1Z 7K4,CANADA

[2] ROYAL OTTAWA HOSP,MENTAL HLTH RES INST,OTTAWA,ON K1Z 7K4,CANADA

来源：

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | 1995年 / 10卷 / 02期

关键词：

MAJOR DEPRESSIVE DISORDER; PANIC DISORDER; DYSTHYMIA; MAOI; RIMA; MOCLOBEMIDE; SSRI; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

D O I：

10.1002/hup.470100205

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

This retrospective study was undertaken with the objective of determining how effective and safe moclobemide, a specific and reversible inhibitor of monoamine oxidase-A (RIMA), is when used in combination with specific serotonin re-uptake inhibitors (SSRIs), in a clinical setting. A thorough chart review was done of all patients with affective and anxiety disorders seen at our centre who received combination treatment with moclobemide and an SSRI. Combination moclobemide-SSRI treatment demonstrated good efficacy in treating treatment-resistant patients. The combination treatment was well tolerated with very few drug interactions. Dosages should be started low, titrated slowly and carefully, and patients should be monitored closely.

引用

页码：105 / 109

页数：5

共 23 条

[1] A COMPARISON OF MOCLOBEMIDE, AMITRIPTYLINE AND PLACEBO IN DEPRESSION - A CANADIAN MULTICENTER STUDY [J].